<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: spinal fractures will", fill: "#555"},
{source: "3: spinal fractures will", target: "3: significant", fill: "#555"},
{source: "3: significant", target: "3: consistent demand", fill: "#555"},
{source: "3: consistent demand", target: "3: KyphX ", fill: "#555"},
{source: "3: KyphX ", target: "3: instruments", fill: "#555"},
{source: "3: spinal fractures will", target: "7: price safety efficacy reliability", fill: "#e2062c"},
{source: "7: price safety efficacy reliability", target: "7: sales efforts", fill: "#e2062c"},
{source: "7: sales efforts", target: "7: availability", fill: "#e2062c"},
{source: "7: availability", target: "7: adequate thirdparty", fill: "#e2062c"},
{source: "7: adequate thirdparty", target: "7: reimbursement", fill: "#e2062c"},
{source: "7: reimbursement", target: "7: procedures using", fill: "#e2062c"},
{source: "7: procedures using", target: "7: new products", fill: "#e2062c"},
{source: "7: new products", target: "7: competing products", fill: "#e2062c"},
{source: "7: competing products", target: "7: general economic conditions affecting", fill: "#e2062c"},
{source: "7: general economic conditions affecting", target: "7: purchasing patterns", fill: "#e2062c"},
{source: "7: price safety efficacy reliability", target: "9: successfully", fill: "#ffd700"},
{source: "9: successfully", target: "9: regulatory approval", fill: "#ffd700"},
{source: "9: regulatory approval", target: "9: manufacture sell", fill: "#ffd700"},
{source: "9: manufacture sell", target: "9: market acceptance", fill: "#ffd700"},
{source: "9: market acceptance", target: "9: new products product extensions", fill: "#ffd700"},
{source: "9: new products product extensions", target: "9: improvements", fill: "#ffd700"},
{source: "9: improvements", target: "9: existing products could adversely affect", fill: "#ffd700"},
{source: "9: existing products could adversely affect", target: "9: condition which could", fill: "#ffd700"},
{source: "9: successfully", target: "10: dependent upon", fill: "#ec5800"},
{source: "10: dependent upon", target: "10: availability", fill: "#ec5800"},
{source: "10: availability", target: "10: adequate physician", fill: "#ec5800"},
{source: "10: adequate physician", target: "10: reimbursement", fill: "#ec5800"},
{source: "10: reimbursement", target: "10: by thirdparty payors", fill: "#ec5800"},
{source: "10: by thirdparty payors", target: "10: balloon kyphoplasty", fill: "#ec5800"},
{source: "10: balloon kyphoplasty", target: "10: procedures using", fill: "#ec5800"},
{source: "10: procedures using", target: "10: instruments", fill: "#ec5800"},
{source: "10: dependent upon", target: "21: governmental", fill: "#4b0082"},
{source: "21: governmental", target: "21: reimbursement", fill: "#4b0082"},
{source: "21: reimbursement", target: "21: instruments", fill: "#4b0082"},
{source: "21: instruments", target: "21: cannot assure", fill: "#4b0082"},
{source: "21: cannot assure", target: "21: technology", fill: "#4b0082"},
{source: "21: technology", target: "21: used will continue", fill: "#4b0082"},
{source: "21: used will continue", target: "21: reimbursed at current rates", fill: "#4b0082"},
{source: "21: reimbursed at current rates", target: "21: thirdparty payors will continue", fill: "#4b0082"},
{source: "21: thirdparty payors will continue", target: "21: costeffective", fill: "#4b0082"},
{source: "21: governmental", target: "25: cannot predict", fill: "#50404d"},
{source: "25: cannot predict", target: "25: impact on", fill: "#50404d"},
{source: "25: impact on", target: "25: legislation", fill: "#50404d"},
{source: "25: legislation", target: "25: regulations", fill: "#50404d"},
{source: "25: regulations", target: "25: healthcare system", fill: "#50404d"},
{source: "25: cannot predict", target: "47: difficulty integrating", fill: "#98ff98"},
{source: "47: difficulty integrating", target: "47: financials operations products", fill: "#98ff98"},
{source: "47: financials operations products", target: "47: technologies into", fill: "#98ff98"},
{source: "47: difficulty integrating", target: "88: Investigations ", fill: "#ffd700"},
{source: "88: Investigations ", target: "88: enforcement", fill: "#ffd700"},
{source: "88: enforcement", target: "88: manufacturers", fill: "#ffd700"},
{source: "88: manufacturers", target: "88: investigations", fill: "#ffd700"},
{source: "88: investigations", target: "88: activities", fill: "#ffd700"},
{source: "88: activities", target: "88: the United States ", fill: "#ffd700"},
{source: "88: the United States ", target: "88: government", fill: "#ffd700"},
{source: "88: government", target: "88: connection with", fill: "#ffd700"},
{source: "88: connection with", target: "88: healthcare professionals", fill: "#ffd700"},
{source: "88: Investigations ", target: "91: operations", fill: "#880085"},
{source: "91: operations", target: "91: laws described", fill: "#880085"},
{source: "91: laws described", target: "91: governmental regulations", fill: "#880085"},
{source: "91: governmental regulations", target: "91: associated adverse consequences such as fines", fill: "#880085"},
{source: "91: associated adverse consequences such as fines", target: "91: penalties exclusion from healthcare programs andor", fill: "#880085"},
{source: "91: penalties exclusion from healthcare programs andor", target: "91: curtailment", fill: "#880085"},
{source: "91: curtailment", target: "91: restructuring", fill: "#880085"},
{source: "91: restructuring", target: "91: operations which could harm", fill: "#880085"},
{source: "91: operations which could harm", target: "91: financial condition", fill: "#880085"},
{source: "91: operations", target: "117: currently manufacture substantially", fill: "#dcdcdc"},
{source: "117: currently manufacture substantially", target: "117: facilities", fill: "#dcdcdc"},
{source: "117: currently manufacture substantially", target: "START_HERE", fill: "#dcdcdc"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgical_instrument">Surgical instrument</a></td>
      <td>A surgical instrument is a tool or device for performing specific actions or carrying out desired effects during a surgery or operation, such as modifying biological tissue, or to provide access for viewing it. Over time, many different kinds of surgical instruments and tools have been invented.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Keyboard_instrument">Keyboard instrument</a></td>
      <td>A keyboard instrument is a musical instrument played using a keyboard, a row of levers which are pressed by the fingers. The most common of these are the piano, organ, and various electronic keyboards, including synthesizers and digital pianos.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Percussion_instrument">Percussion instrument</a></td>
      <td>A percussion instrument is a musical instrument that is sounded by being struck or scraped by a beater including attached or enclosed beaters or rattles struck, scraped or rubbed by hand or struck against another similar instrument. Excluding zoomusicological instruments and the human voice, the percussion family is believed to include the oldest musical instruments.The percussion section of an orchestra most commonly contains instruments such as the timpani, snare drum, bass drum, cymbals, triangle and tambourine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/String_instrument">String instrument</a></td>
      <td>String instruments, stringed instruments, or chordophones are musical instruments that produce sound from vibrating strings when a performer plays or sounds the strings in some manner.\nMusicians play some string instruments by plucking the strings with their fingers or a plectrum—and others by hitting the strings with a light wooden hammer or by rubbing the strings with a bow.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_instrument">Financial instrument</a></td>
      <td>Financial instruments are monetary contracts between parties. They can be created, traded, modified and settled.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Folk_instrument">Folk instrument</a></td>
      <td>A folk instrument is a musical instrument that developed among common people and usually does not have a known inventor. It can be made from wood, metal or other material.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ERISA_reimbursement">ERISA reimbursement</a></td>
      <td>In the United States, ERISA reimbursement refers to the efforts of an ERISA Plan administrator (an insurer) to obtain repayment from an insured person who had previously received payments for personal injury medical bills.When an insurer pays a injury claim to someone, the insurer can seize cash settlements from whoever caused the injury. This “right of reimbursement” is essentially a subrogation claim.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_mileage_reimbursement_rate">Business mileage reimbursement rate</a></td>
      <td>The business mileage reimbursement rate is an optional standard mileage rate used in the United States for purposes of computing the allowable business deduction, for Federal income tax purposes under the Internal Revenue Code, at 26 U.S.C. § 162, for the business use of a vehicle. Under the law, the taxpayer for each year is generally entitled to deduct either the actual expense amount, or an amount computed using the standard mileage rate, whichever is greater.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_reimbursement_account">Health reimbursement account</a></td>
      <td>A Health Reimbursement Account, formally a Health Reimbursement Arrangement (HRA), is a type of US employer-funded health benefit plan that reimburses employees for out-of-pocket medical expenses and, in limited cases, to pay for health insurance plan premiums.An HRA is not truly an account, since it does not place funds under a separate legal title. Instead, it is an agreement under which the employee can submit qualified health expenses to the employer for reimbursement.Following implementation of the Affordable Care Act, HRAs must be integrated with a qualified employer-sponsored group health insurance plan to avoid excise tax penalties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capitation_(healthcare)">Capitation (healthcare)</a></td>
      <td>Capitation is a payment arrangement for health care service providers. It pays a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fee_Reimbursement_Scheme_(Andhra_Pradesh)">Fee Reimbursement Scheme (Andhra Pradesh)</a></td>
      <td>The Fee Reimbursement Scheme (also known as the Post-matric Scholarship Scheme) is a student education sponsorship programme of the Government of Andhra Pradesh. It supports students from lower economic strata in the state.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diagnosis-related_group">Diagnosis-related group</a></td>
      <td>Diagnosis-related group (DRG) is a system to classify hospital cases into one of originally 467 groups, with the last group (coded as 470 through v24, 999 thereafter) being "Ungroupable". This system of classification was developed as a collaborative project by Robert B Fetter, PhD, of the Yale School of Management, and John D. Thompson, MPH, of the Yale School of Public Health.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vertebral_augmentation">Vertebral augmentation</a></td>
      <td>Vertebral augmentation, including vertebroplasty and kyphoplasty, refers to similar percutaneous spinal procedures in which bone cement is injected through a small hole in the skin into a fractured vertebra in order to relieve back pain caused by a vertebral compression fracture. After decades of medical research into the efficacy and safety of vertebral augmentation, there is still a lack of consensus regarding certain aspects of vertebroplasty and kyphoplasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vehicle_emission_standard">Vehicle emission standard</a></td>
      <td>Emission standards  are the legal requirements governing air pollutants released into the atmosphere. Emission standards set quantitative limits on the permissible amount of specific air pollutants that may be released from specific sources over specific timeframes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_director">Operations director</a></td>
      <td>The role of operations director generally encompasses the oversight of operational aspects of company strategy with responsibilities to ensure operation information is supplied to the chief executive and the board of directors as well as external parties.\n\n\n== Description ==\nThe role of operations director can vary according to the size of a company, and at some companies many even encompass some or all the functions of a chief operating officer.The Institute of Directors of the United Kingdom defines the role as overseeing "all operational aspects of company strategy" and "responsible for the flow of operations information to the chief executive, the board and, where necessary, external parties such as investors or financial institutions".</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>KYPHON INC      ITEM 1A RISK FACTORS       Factors Affecting Future Operating Results          Our  <font color="blue"><font color="blue">future success</font> depends on</font> our ability to develop and <font color="blue">successfully</font>     introduce <font color="blue">new products</font>, product <font color="blue">extensions</font> and <font color="blue">improvements</font> to existing     products to <font color="blue">address unmet patient</font> and market needs</td>
    </tr>
    <tr>
      <td>Our  current  products  offer  <font color="blue">orthopaedic surgeons</font> and <font color="blue">neurosurgeons</font>,     <font color="blue">interventional radiologists</font> and <font color="blue">interventional neuroradiologists</font> the ability     to treat and <font color="blue">restore spinal anatomy during <font color="blue">balloon <font color="blue">kyphoplasty</font></font></font></td>
    </tr>
    <tr>
      <td>We cannot     assure  you that the market for the treatment of <font color="blue">spinal fractures will</font>     continue  to  generate  <font color="blue">significant</font> or <font color="blue"><font color="blue">consistent</font> demand</font> for our <font color="blue">KyphX     </font><font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>Demand for our products could be <font color="blue">significant</font>ly diminished by     <font color="blue">alternative</font> treatment methods, and by new <font color="blue">technologies</font> or products that     replace  and render our products obsolete or too expensive</td>
    </tr>
    <tr>
      <td>Our future     success is <font color="blue">dependent upon</font>, among other factors, our ability to develop,     obtain <font color="blue">regulatory clearance</font> or approval for, <font color="blue">manufacture</font>, sell and achieve     <font color="blue">market acceptance</font> of <font color="blue">new products</font>, product <font color="blue">extensions</font> and <font color="blue">improvements</font> to     our <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>The extent of, and rate at which, <font color="blue">market acceptance</font>     and  <font color="blue">penetration</font> are achieved <font color="blue">by future products</font> is a function of many     variables</td>
    </tr>
    <tr>
      <td>These variables include price, safety, efficacy, <font color="blue">reliability</font>,     marketing  and <font color="blue">sales efforts</font>, the <font color="blue">availability</font> of adequate third-party     coverage and <font color="blue">reimbursement</font> for <font color="blue">procedures using</font> our <font color="blue">new products</font> and the     existence of <font color="blue">competing products</font> and <font color="blue">general economic conditions affecting</font>     <font color="blue">purchasing patterns</font></td>
    </tr>
    <tr>
      <td>Our ability to market and sell <font color="blue">new products</font>, product     <font color="blue">extensions</font> and <font color="blue">improvements</font> to our <font color="blue">existing products</font> may also be subject to     <font color="blue">government</font> regulation, including clearance and <font color="blue">approval by</font> the FDA and     foreign <font color="blue">government</font> agencies</td>
    </tr>
    <tr>
      <td>Any failure in our ability to <font color="blue">successfully</font>     develop, obtain <font color="blue">regulatory approval</font> for, <font color="blue">manufacture</font>, sell and achieve     <font color="blue">market acceptance</font> of our <font color="blue">new products</font>, product <font color="blue">extensions</font> or <font color="blue">improvements</font> to     our <font color="blue">existing products</font> <font color="blue">could <font color="blue">adversely</font> affect</font> our business and our financial     condition, <font color="blue">which could</font> cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">dependent upon</font> the <font color="blue">availability</font> of <font color="blue">adequate physician</font> and     hospital  <font color="blue">reimbursement</font>  by third-party payors for <font color="blue">balloon <font color="blue">kyphoplasty</font></font>     <font color="blue">procedures using</font> our KyphX <font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>Our  ability  to  <font color="blue">commercialize</font>  our  products <font color="blue">successfully</font> depends in     <font color="blue">significant</font>  part  on  the  extent  to  <font color="blue">which appropriate coverage</font> and     <font color="blue">reimbursement</font> for our products and related procedures are obtained from     third-party  payors,  including  <font color="blue">government</font>al payors such as Medicare</td>
    </tr>
    <tr>
      <td><font color="blue">Un<font color="blue">certainty</font>  </font>exists as to the coverage and <font color="blue">reimbursement</font> status of new     medical <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Procedures </font>using our KyphX <font color="blue">instruments</font> are currently     covered and <font color="blue">reimbursed by</font> the Medicare program and other <font color="blue">government</font>al and     private third-party payors</td>
    </tr>
    <tr>
      <td>However, as a result of <font color="blue"><font color="blue">development</font>s</font> in both     physician and hospital <font color="blue">reimbursement</font>, including the <font color="blue">establishment</font> of new     <font color="blue">reimbursement</font> codes describing <font color="blue">kyphoplasty</font>, some physicians and hospitals in     some states may believe that the level of <font color="blue">reimbursement</font> they receive is too     low to support performing <font color="blue">balloon <font color="blue">kyphoplasty</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Continued </font>use of our <font color="blue">KyphX     </font><font color="blue">instruments</font> by the <font color="blue">medical community may</font> be <font color="blue"><font color="blue">adversely</font> impacted</font> if physicians     perceive that they do not receive sufficient <font color="blue">reimbursement</font> from third-party     payors  for  their  services  in  performing  the <font color="blue">procedures using</font> our     <font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>As of now, it is not possible to assess with any degree of     <font color="blue">certainty</font> whether the <font color="blue">implementation</font> of recent <font color="blue">reimbursement</font> code changes     has had or will have any material <font color="blue">impact on</font> the behavior of <font color="blue">clinicians</font> with     respect to their interest in performing the <font color="blue">balloon <font color="blue">kyphoplasty</font></font> procedure</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">reimbursement</font> for competing procedures, such as <font color="blue">vertebroplasty</font>,     <font color="blue">may also continue</font> to be perceived in some cases as more favorable for the     physician or <font color="blue">hospital than</font> that available for using our products and thus     may reduce the frequency with which <font color="blue">balloon <font color="blue">kyphoplasty</font></font> <font color="blue">procedures using</font> our     products are performed, <font color="blue"><font color="blue">which could</font> harm</font> our revenues</td>
    </tr>
    <tr>
      <td>If domestic or <font color="blue">international</font> third-party payors <font color="blue">adversely</font> change coverage or     <font color="blue">reimbursement</font> policies for <font color="blue">balloon <font color="blue">kyphoplasty</font></font> procedures, our ability to     market and sell our KyphX <font color="blue">instruments</font> would be <font color="blue"><font color="blue">adversely</font> impacted</font>, which     would harm our business, revenues and operating results</td>
    </tr>
    <tr>
      <td>Third-party  payors, including Medicare and private health maintenance     <font color="blue"><font color="blue">organization</font>s</font> and insurance plans, are <font color="blue">increasingly</font> <font color="blue">challenging</font> the prices     charged for medical products and services and may institute adverse changes     in  their  coverage  or <font color="blue">reimbursement</font> policies for <font color="blue">balloon <font color="blue">kyphoplasty</font></font>     procedures</td>
    </tr>
    <tr>
      <td><font color="blue">Governmental </font>and private third-party payors are developing     <font color="blue">increasingly</font> <font color="blue">sophisticated</font> methods of <font color="blue">controlling</font> healthcare costs and are     exploring more cost-<font color="blue">effective</font> methods of delivering healthcare, including     the placement of <font color="blue">limitations</font> on the <font color="blue">circumstances</font> under which a procedure is     covered  and  other  <font color="blue">restrictions</font></td>
    </tr>
    <tr>
      <td>While many <font color="blue">government</font>al and private     third-party payors currently provide coverage and <font color="blue">reimbursement</font> for the     procedures in which our KyphX <font color="blue">instruments</font> are used, we <font color="blue">cannot assure</font> you     that  procedures  in  which our <font color="blue">technology</font> is <font color="blue">used will continue</font> to be     <font color="blue">reimbursed at current rates</font> or that third-party payors will continue to     consider  our  <font color="blue">technology</font>  cost-<font color="blue">effective</font>  and  provide  coverage  and     <font color="blue">reimbursement</font> for our <font color="blue">technology</font>, in whole or in part</td>
    </tr>
    <tr>
      <td>If third-party payors     <font color="blue">adopt new limits</font> or <font color="blue">restrictions</font> on coverage and <font color="blue">reimbursement</font> of balloon     <font color="blue">kyphoplasty</font> procedures, such a <font color="blue">development</font> could <font color="blue">significant</font>ly impact the     <font color="blue">willingness</font> of hospitals, clinics and doctors to purchase and use our <font color="blue">KyphX     </font><font color="blue">instruments</font>, which in turn <font color="blue">could <font color="blue">adversely</font> affect</font> our business and our     <font color="blue">financial condition</font>, <font color="blue">which could</font> cause our stock price to decline</td>
    </tr>
    <tr>
      <td>In the United States, there have been and we expect <font color="blue">there will continue</font> to     be a number of <font color="blue">legislative</font> and <font color="blue">regulatory proposals</font> to change the healthcare     system, including the Medicare program, and some could involve changes that     could  <font color="blue">significant</font>ly affect our business</td>
    </tr>
    <tr>
      <td>Future <font color="blue">legislative</font> or policy     <font color="blue">initiatives directed at increasing</font> the <font color="blue">accessibility</font> of healthcare and     <font color="blue">reducing <font color="blue">costs could</font></font> be <font color="blue">introduced on either</font> the Federal or state level</td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot predict</font> the <font color="blue">impact on</font> our business of any <font color="blue">legislation</font> or <font color="blue">regulations</font>     related to the <font color="blue">healthcare system</font> that may be enacted or adopted in the     future</td>
    </tr>
    <tr>
      <td>In addition, healthcare cost containment efforts similar to those we     face in the <font color="blue">United States </font>are prevalent in many of the other countries in     which we intend to, or already do, sell our <font color="blue">instruments</font>, and these efforts     are expected to continue in both the <font color="blue">United States </font>and abroad</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement     </font>and healthcare payment systems in <font color="blue">international</font> markets vary <font color="blue">significant</font>ly     by country and include both <font color="blue">government</font>-sponsored healthcare and private     insurance</td>
    </tr>
    <tr>
      <td>Given that the vast majority of our revenues indirectly rely on     <font color="blue">government</font>-funded health care systems that reimburse our customers for their     use of our products to <font color="blue">treat patients</font>, any adverse change in <font color="blue">government</font>al     payors &amp;apos  coverage and/or <font color="blue">reimbursement</font> policies, including as a result of     reaction to rapidly escalating budget pressures, would <font color="blue">adversely</font> impact our     ability to market and sell our KyphX <font color="blue">instruments</font>, harm our business and     reduce our revenues</td>
    </tr>
    <tr>
      <td>The absence of prospective, randomized, controlled clinical trial data as     support  for  the <font color="blue">economic differentiation</font> of <font color="blue">balloon <font color="blue">kyphoplasty</font></font> over     <font color="blue">vertebroplasty</font>  is causing some <font color="blue">influential physicians</font> in positions of     authority to speak <font color="blue">out against adoption</font> of <font color="blue">balloon <font color="blue">kyphoplasty</font></font>, which may     <font color="blue">ultimately <font color="blue">adversely</font> affect</font> our business and our <font color="blue">financial condition</font>, which     could cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Over  the past year or so, a handful of vocal physicians have begun to     publicly criticize the cost and merits of <font color="blue">balloon <font color="blue">kyphoplasty</font></font> as a procedure     for treating vertebral <font color="blue">compression</font> fractures</td>
    </tr>
    <tr>
      <td>We believe this is due, in     part, to the absence to-date of prospective, randomized, controlled clinical     <font color="blue">trial data on</font> the <font color="blue"><font color="blue">effective</font>ness</font> of <font color="blue">balloon <font color="blue">kyphoplasty</font></font> and the perceived     economic cost difference between <font color="blue">balloon <font color="blue">kyphoplasty</font></font> and <font color="blue">vertebroplasty</font></td>
    </tr>
    <tr>
      <td>On     more than one occasion, certain speakers, including a <font color="blue">few physicians</font> of     authority in <font color="blue">various institutions</font> and <font color="blue">professional societies</font>, have publicly     stated their opposition to both <font color="blue">balloon <font color="blue">kyphoplasty</font></font> and Kyphon <font color="blue">based on</font> this     lack of perceived <font color="blue">justification</font> for the cost or economics of the procedure</td>
    </tr>
    <tr>
      <td>We have recently completed <font color="blue">enrollment</font> in a randomized, controlled trial     comparing <font color="blue">balloon <font color="blue">kyphoplasty</font></font> versus non-surgical <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>We do not yet     know what <font color="blue"><font color="blue">clinical outcome</font>s</font> that trial will reveal, or whether the trialapstas     results, once available, will demonstrate the benefits of treatment of     vertebral <font color="blue">compression</font> fractures with <font color="blue">balloon <font color="blue">kyphoplasty</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font>     predict  how  the <font color="blue">current negative public criticism</font> to adoption of our     products for <font color="blue">treating patients ultimately may affect</font> our business or our     revenues</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">primary care</font> physicians</font> are unwilling or unable to <font color="blue">refer patients</font> to     trained  <font color="blue">clinicians</font>  that  use  our  KyphX products to perform balloon     <font color="blue">kyphoplasty</font>, our <font color="blue"><font color="blue">revenues will</font> suffer</font> and our business may not expand or may     decline</td>
    </tr>
    <tr>
      <td>A key element of our business strategy is to educate <font color="blue"><font color="blue">primary care</font> physicians</font>     and <font color="blue">spine specialists on</font> the use of our KyphX <font color="blue">instruments</font> as an <font color="blue">alternative</font>     to <font color="blue">conventional spinal fracture treatment</font> and <font color="blue">conservative pain <font color="blue">management</font></font>     therapies</td>
    </tr>
    <tr>
      <td>We  believe <font color="blue">primary care</font> is an important source of patient     referral, and, therefore, it is important to <font color="blue">educate them about</font> our products     and the <font color="blue">clinical outcome</font> of the <font color="blue">balloon <font color="blue">kyphoplasty</font></font> procedure</td>
    </tr>
    <tr>
      <td>We believe     that <font color="blue"><font color="blue">primary care</font> physicians</font> and <font color="blue">spine specialists may</font> not <font color="blue">widely adopt</font> our     <font color="blue">products unless</font> they determine, <font color="blue">based on</font> experience, <font color="blue">clinical data</font> and     published,  peer- <font color="blue">reviewed journal articles</font>, that our <font color="blue">products provide</font>     benefits or an attractive <font color="blue">alternative</font> to <font color="blue">conventional treatments</font> of spinal     fractures</td>
    </tr>
    <tr>
      <td>In addition, we believe that <font color="blue">recommendations</font> and support of our     products by influential practitioners are essential for <font color="blue">market acceptance</font>     and adoption of our products</td>
    </tr>
    <tr>
      <td>If we are unable to have <font color="blue">continued referrals</font>     from <font color="blue"><font color="blue">primary care</font> physicians</font>, then our <font color="blue"><font color="blue">future growth</font> will</font> be harmed and our     business may decline</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font> integrate into our business InnoSpine, Inc</td>
    </tr>
    <tr>
      <td>or  any  other  <font color="blue">acquisitions</font> we may choose to make, we <font color="blue">could encounter</font>     <font color="blue"><font color="blue">difficult</font>ies</font> that harm our business</td>
    </tr>
    <tr>
      <td>We recently acquired InnoSpine, Inc</td>
    </tr>
    <tr>
      <td>and a <font color="blue">technology</font> that we have not dealt     with before</td>
    </tr>
    <tr>
      <td>We may also acquire other companies, products or <font color="blue">technologies</font>     that we believe to be <font color="blue">complementary</font> to the present or <font color="blue">future direction</font> of     our business</td>
    </tr>
    <tr>
      <td>We may have <font color="blue"><font color="blue">difficult</font>y integrating</font> the acquired personnel,     financials, <font color="blue">operations</font>, products or <font color="blue">technologies</font> into our existing business</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font>and the resulting <font color="blue">integration may dilute</font> our <font color="blue">earnings per</font>     share,  harm our liquidity, disrupt our ongoing business, distract our     <font color="blue">management</font> and employees, increase our expenses, create an unfavorable     <font color="blue">impression</font> of our company in the <font color="blue">public markets</font> for our equity, and expose     us to new risks and <font color="blue">liabilities</font>, any or all of <font color="blue"><font color="blue">which could</font> harm</font> our business     and cause our stock price to decline</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we may face <font color="blue">significant</font> <font color="blue">competition</font> from other <font color="blue">companies with</font>     <font color="blue">greater resources</font> or superior <font color="blue">technology</font> than we have, we may be unable to     maintain our <font color="blue"><font color="blue">competitive</font> position</font> and sales of our KyphX <font color="blue">instruments</font> may     decline</td>
    </tr>
    <tr>
      <td>The market for <font color="blue">medical devices</font> is <font color="blue">intensely <font color="blue">competitive</font></font>, subject to rapid     change and <font color="blue">significant</font>ly affected by new product <font color="blue">introduction</font>s and other     <font color="blue">market <font color="blue">activities</font></font> of <font color="blue">industry participants</font></td>
    </tr>
    <tr>
      <td>While the direct <font color="blue">competition</font> we     have faced to date has been limited, we are aware that several companies,     some  with more resources than ours, are developing and may already be     introducing products to directly compete with ours in similar procedures,     both in the <font color="blue">United States </font>and abroad, including, in some instances, copies     of our <font color="blue">technology</font> for <font color="blue">distribution</font> in one or more foreign markets</td>
    </tr>
    <tr>
      <td>Some of     these  <font color="blue">competitors</font> &amp;apos   products may be successful as a result of greater     efficacy, less expensive <font color="blue">alternative</font>s to our products, or another advantage     that  makes  their  products  more  attractive  than ours, <font color="blue">which could</font>     <font color="blue">significant</font>ly impact our <font color="blue">reimbursement</font> levels, anticipated revenues and     <font color="blue">future growth</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">industry also</font> includes large <font color="blue">pharmaceutical companies</font>     that  are  developing  drug  products that may reduce the incidence of     <font color="blue">osteoporosis</font>  and  cancer  and,  therefore,  the  market for our <font color="blue">KyphX     </font><font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>Our ability to compete <font color="blue">successfully</font> depends in part on our     ability to respond quickly to medical and <font color="blue">technological</font> changes and user     <font color="blue">preferences through</font> the <font color="blue">development</font> and <font color="blue">introduction</font> of <font color="blue">new products</font> that     are of <font color="blue">high quality</font> and <font color="blue">address patient</font> and <font color="blue">surgeon requirements</font></td>
    </tr>
    <tr>
      <td>We compete     with many <font color="blue">larger companies</font> that <font color="blue">enjoy <font color="blue"><font color="blue">competitive</font> advantage</font>s</font>, including:       * longer-standing <font color="blue">distribution</font> networks and <font color="blue">relationships with healthcare</font>         providers and payors;       * <font color="blue"><font color="blue">additional</font> lines</font> of products and the ability to <font color="blue">bundle products</font> to offer         <font color="blue">higher discounts</font> or other <font color="blue">incentives</font> to gain a <font color="blue"><font color="blue">competitive</font> advantage</font>;       * greater experience completing <font color="blue">preclinical testing</font> and <font color="blue">clinical trials</font>         and obtaining FDA and other <font color="blue">regulatory approval</font>s; and       * <font color="blue">greater resources</font> for product <font color="blue">development</font>, <font color="blue">manufacturing</font>, sales and         marketing and <font color="blue">patent <font color="blue">litigation</font></font></td>
    </tr>
    <tr>
      <td>If  we  are  unable  to <font color="blue">compete <font color="blue">effective</font>ly against existing</font> or future     <font color="blue">competitors</font>, sales of our <font color="blue">instruments</font> will decline</td>
    </tr>
    <tr>
      <td>If  we are unable to <font color="blue">prevent <font color="blue">third parties</font> from using</font> our <font color="blue">intellectual</font>     property, our ability to compete in the <font color="blue">market will</font> be harmed</td>
    </tr>
    <tr>
      <td>We believe that the <font color="blue">proprietary</font> <font color="blue">technology</font> embodied in our <font color="blue">instruments</font> and     <font color="blue">methods gives us</font> a <font color="blue"><font color="blue">competitive</font> advantage</font></td>
    </tr>
    <tr>
      <td><font color="blue">Maintaining </font>this <font color="blue">competitive</font>     advantage is important to our <font color="blue">future success</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on patent protection</font>     in the US and abroad, as well as on a <font color="blue">combination</font> of copyright, trade     secret and trademark laws, to protect our <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>However,     these legal means <font color="blue">afford only</font> limited protection and may not <font color="blue">adequately</font>     protect our rights or <font color="blue">permit us</font> to gain or keep any <font color="blue"><font color="blue">competitive</font> advantage</font></td>
    </tr>
    <tr>
      <td>For example, our <font color="blue">patents may</font> be challenged, invalidated or <font color="blue">circumvented by</font>     <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Our two earliest patents, which we believe <font color="blue">provide broad</font>     protection to our <font color="blue">technology</font>, expire <font color="blue">as early as</font> <font color="blue">February </font>2009</td>
    </tr>
    <tr>
      <td>Our patent     <font color="blue"><font color="blue"><font color="blue">application</font>s</font> may</font> not <font color="blue">issue as patents at</font> all or in a form that will be     <font color="blue">advantageous</font>  to  us</td>
    </tr>
    <tr>
      <td>We  may not be able to prevent the <font color="blue">unauthorized</font>     <font color="blue">disclosure</font> or use of our <font color="blue">technical knowledge</font> or other <font color="blue">trade secrets by</font>     consultants, vendors, former employees and current employees, despite the     existence  of  non<font color="blue">disclosure</font>  and <font color="blue">confidentiality <font color="blue">agreement</font>s</font> and other     contractual <font color="blue">restrictions</font></td>
    </tr>
    <tr>
      <td>Furthermore, the laws of <font color="blue">foreign countries</font> may not     protect our <font color="blue">intellectual</font> property rights to the <font color="blue">same extent as</font> the laws of     the <font color="blue">United States </font>and may permit others to copy our products abroad without     <font color="blue">effective</font> recourse</td>
    </tr>
    <tr>
      <td>We have recently detected what we believe are the first     attempts  to copy some of our products for <font color="blue">distribution</font> in one or more     <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>In addition, in many foreign jurisdictions, we have     either  acquired  patent protection that is narrower in scope than our     <font color="blue">corresponding</font>  protection  in the US or chosen, for various business     reasons, not to pursue any patent protection at all</td>
    </tr>
    <tr>
      <td>We also may not have     the ability to <font color="blue">prevent infringing products from remaining on</font> the market in     at least some <font color="blue">geographic locations</font>, and we <font color="blue">may lose market</font> share or have our     <font color="blue">growth impeded</font> in those <font color="blue"><font color="blue">geographic markets</font> as</font> a result</td>
    </tr>
    <tr>
      <td>To protect our     rights, we may in the <font color="blue">future initiate</font> other claims or <font color="blue"><font color="blue">litigation</font> against</font>     <font color="blue">third parties</font> for <font color="blue">infringement</font> of our <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also begin</font>     one or more patent proceedings in <font color="blue">various administrative agencies</font> and patent     offices to protect our <font color="blue">patent rights</font> and <font color="blue">prevent them from</font> being undermined     by our <font color="blue">competitors</font> &amp;apos  <font color="blue">patent filings</font></td>
    </tr>
    <tr>
      <td>If we decide to enforce our <font color="blue">intellectual</font> property rights to prevent or     <font color="blue">inhibit appropriation</font> of our <font color="blue">technology</font> by <font color="blue">competitors</font>, that <font color="blue">process will</font> be     expensive and time consuming to litigate or <font color="blue">otherwise dispose</font> of, will     divert <font color="blue">management</font>apstas <font color="blue">attention from</font> our core business, and may harm our     business if we do not prevail</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">instruments</font> could infringe on the <font color="blue">intellectual</font> property rights of     others, which may lead to costly <font color="blue">litigation</font>, payment of substantial damages     or royalties and/or our <font color="blue">inability</font> to use essential <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The medical device industry has <font color="blue">been characterized by</font> extensive <font color="blue">litigation</font>     and <font color="blue">administrative proceedings</font> regarding patents and other <font color="blue">intellectual</font>     property  rights</td>
    </tr>
    <tr>
      <td>Whether a medical device infringes a patent involves     complex  legal and factual issues, the <font color="blue">de<font color="blue">termination</font></font> of which is often     uncertain</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may assert that our <font color="blue">instruments</font> and methods     infringe their patents, especially as we expand our business into other     areas of <font color="blue">technology</font> for <font color="blue">diagnosis</font> and treatment of <font color="blue">spinal conditions</font></td>
    </tr>
    <tr>
      <td><font color="blue">From     </font>time to time, we receive correspondence from various <font color="blue">third parties</font> accusing     us of infringing their patents or <font color="blue">inviting us</font> to license their patents</td>
    </tr>
    <tr>
      <td>In     addition, they may claim that their patents have <font color="blue">priority over ours</font> because     they <font color="blue">invented first</font> or their patents were filed or <font color="blue">issued first</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>   <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> can take many years to issue, there may be <font color="blue"><font color="blue">application</font>s</font>     now pending of which we may be aware or unaware, which may later result in     <font color="blue">issued patents</font> that our <font color="blue">instruments</font> or <font color="blue"><font color="blue">methods may</font> infringe</font></td>
    </tr>
    <tr>
      <td>There could     also be <font color="blue">existing patents</font> that one or more of our <font color="blue">instruments</font> or <font color="blue">methods may</font>     <font color="blue">inadvertently</font> be infringing</td>
    </tr>
    <tr>
      <td>As the number of <font color="blue">competitors</font> in the market for     <font color="blue">minimally invasive spine disorder treatments grow</font>, the <font color="blue">possibility</font> of a     patent <font color="blue">infringement</font> claim <font color="blue"><font color="blue">against us</font> increases</font></td>
    </tr>
    <tr>
      <td><font color="blue">Infringement </font>and other <font color="blue">intellectual</font> property claims, with or <font color="blue">without merit</font>,     <font color="blue">against us</font> can be expensive and time-consuming to litigate or otherwise     dispose of and can divert <font color="blue">management</font>apstas <font color="blue">attention from</font> our core business</td>
    </tr>
    <tr>
      <td>In     addition, if we lose an <font color="blue">intellectual</font> property <font color="blue">litigation</font> matter, a court     could require us to pay substantial damages and royalties, as well as issue     a  <font color="blue">preliminary</font>  or  permanent  injunction  that <font color="blue">would prohibit us from</font>     developing, <font color="blue">manufacturing</font> or selling our products</td>
    </tr>
    <tr>
      <td>Also, although we may     seek to obtain a <font color="blue">license under</font> a <font color="blue">third party</font>apstas <font color="blue">intellectual</font> property rights     to bring an end to any claims or actions asserted or threatened <font color="blue">against us</font>     or to address an injunction or simply if we believe it makes business sense     to do so, we may not be able to obtain a <font color="blue">license on reasonable terms</font> or at     all</td>
    </tr>
    <tr>
      <td>If we cannot design around a patent, are <font color="blue">enjoined from infringing</font> it,     and cannot obtain a satisfactory license, we may be forced to <font color="blue">cease selling</font>     our products, <font color="blue">which could</font> cause substantial harm to our business</td>
    </tr>
    <tr>
      <td>We expend considerable <font color="blue">effort complying with federal</font> and state healthcare      &amp;quote fraud and abuse &amp;quote  laws, but, if we are found not to have <font color="blue">fully complied with</font>     such laws, our business and <font color="blue"><font color="blue">financial condition</font> could</font> be <font color="blue"><font color="blue">adversely</font> affected</font>,     <font color="blue">which could</font> cause our stock price to decline</td>
    </tr>
    <tr>
      <td>As part of the medical device industry, we are subject to <font color="blue">various federal</font>     and  state  healthcare  laws <font color="blue">generally</font> collectively referred to as the     healthcare  &amp;quote fraud and abuse &amp;quote  laws</td>
    </tr>
    <tr>
      <td><font color="blue">Investigations </font>and <font color="blue">enforcement</font> under     these  laws within our industry is increasing, and at least five other     medical  device  <font color="blue"><font color="blue">manufacture</font>rs</font>  have  recently  been  the  subject  of     <font color="blue"><font color="blue">investigation</font>s</font> and/or <font color="blue">enforcement</font> <font color="blue">activities</font> by the <font color="blue">United States </font><font color="blue">government</font>     in  <font color="blue"><font color="blue">connection</font> with</font> the industryapstas interactions with, and payments to,     <font color="blue">healthcare professionals</font></td>
    </tr>
    <tr>
      <td>While we educate and train our employees on how to     interact appropriately with healthcare providers under applicable laws, and     while we believe we are in substantial <font color="blue">compliance with</font> these laws, we cannot     assure you that we will not be subject to <font color="blue"><font color="blue">investigation</font>s</font> or <font color="blue">enforcement</font>     actions under any of these laws <font color="blue">based on</font> the actions of our employees</td>
    </tr>
    <tr>
      <td>We     <font color="blue">may also face <font color="blue">increased risk</font></font> of <font color="blue">investigation</font> and <font color="blue">enforcement</font> <font color="blue">based on</font> the     actions of our <font color="blue">customers under</font> these same laws</td>
    </tr>
    <tr>
      <td>If our past or present     <font color="blue">operations</font> are judged to be in violation of any of the <font color="blue">laws described</font> above     or the other similar <font color="blue">government</font>al <font color="blue">regulations</font> to which we are subject, we     may  ultimately  face  associated adverse <font color="blue">consequences</font>, such as fines,     penalties, exclusion from healthcare programs and/or the <font color="blue">curtailment</font> and     <font color="blue">restructuring</font> of our <font color="blue">operations</font>, <font color="blue"><font color="blue">which could</font> harm</font> our business and our     <font color="blue">financial condition</font> and cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Any <font color="blue">action against</font>     us for violation of these laws, even if we <font color="blue">successfully</font> defend against it,     could cause us to incur <font color="blue">significant</font> legal expenses, divert our <font color="blue">management</font>apstas     <font color="blue">attention from</font> the operation of our business and damage our reputation</td>
    </tr>
    <tr>
      <td>This,  in  turn, <font color="blue">could <font color="blue">adversely</font> affect</font> our business and our financial     condition, <font color="blue">which could</font> cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Our failure to maintain <font color="blue">necessary</font> <font color="blue">regulatory clearance</font>s or approvals, or to     obtain <font color="blue">additional</font> <font color="blue">regulatory clearance</font>s or approvals, in the US and abroad     <font color="blue">could hurt</font> our ability to <font color="blue">commercially</font> distribute and market our <font color="blue">KyphX     </font><font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>Our KyphX <font color="blue">instruments</font> and <font color="blue">bone cement</font> and our KyphOs <font color="blue">calcium phosphate</font> are     considered <font color="blue">medical devices</font> and are subject to extensive regulation in the     <font color="blue">United States </font>and in <font color="blue">foreign countries</font> where we <font color="blue">currently conduct</font>, or intend     to conduct, our business</td>
    </tr>
    <tr>
      <td>Unless an exemption applies, each medical device     that we wish to market in the <font color="blue">United States </font>must first receive either 510(k)     clearance or <font color="blue"><font color="blue">premarket approval</font> from</font> the FDA The FDAapstas 510(k) clearance     <font color="blue">process usually</font> takes from three to 12 months, but may take longer</td>
    </tr>
    <tr>
      <td>The     <font color="blue"><font color="blue">premarket approval</font> process <font color="blue">generally</font></font> takes from one to <font color="blue">three years from</font> the     time the <font color="blue">application</font> is <font color="blue">filed with</font> the FDA, but it can take longer, require     more  information, and be <font color="blue">significant</font>ly more <font color="blue">expensive than</font> the 510(k)     <font color="blue">clearance process</font></td>
    </tr>
    <tr>
      <td>So far, we have obtained 510(k) clearance for the <font color="blue">KyphX     </font>Inflatable Bone Tamps for fracture reduction or void creation in specific     sites including the spine (including for use during <font color="blue">balloon <font color="blue">kyphoplasty</font></font>     using our <font color="blue">bone cement</font>), hand, tibia, radius and <font color="blue">calcaneus</font>, and clearance for     our KyphX HV- R Bone Cement for the treatment of <font color="blue">pathological fractures</font> of     the vertebral body due to <font color="blue">osteoporosis</font>, cancer, or <font color="blue">benign lesions during</font>     balloon  <font color="blue">kyphoplasty</font>  procedures</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">clearances</font> allow us</font> to promote     numerous short- and long-term clinical benefits associated with balloon     <font color="blue">kyphoplasty</font> procedures</td>
    </tr>
    <tr>
      <td>We have <font color="blue">also procured</font> CE marking for promoting our     products in Europe and the appropriate <font color="blue">government</font>al <font color="blue">regulatory clearance</font>s to     conduct  business  in  <font color="blue">Canada  </font>and  several  other  <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>Nevertheless, our 510(k) and foreign <font color="blue">regulatory clearance</font>s can be revoked if     safety or <font color="blue"><font color="blue">effective</font>ness</font> problems develop</td>
    </tr>
    <tr>
      <td>We also will be required to obtain     510(k) clearance or <font color="blue">premarket approval</font> and foreign <font color="blue">regulatory clearance</font>s to     market <font color="blue">additional</font> products, such as new biomaterials for use in balloon     <font color="blue">kyphoplasty</font>, which will likely require <font color="blue">clinical data</font>, and to market our     <font color="blue">existing products</font> for new indications, such as treatment of fractures caused     by trauma, or in <font color="blue">new geographic jurisdictions</font> for us, such as Japan</td>
    </tr>
    <tr>
      <td>If the     <font color="blue">clinical data</font> gathered are not supportive, then <font color="blue"><font color="blue">application</font>s</font> will not be     filed</td>
    </tr>
    <tr>
      <td>If we choose to <font color="blue">seek <font color="blue">additional</font> <font color="blue">clearances</font></font> or <font color="blue">approvals by filing one</font>     or more <font color="blue"><font color="blue">application</font>s</font>, we cannot be certain that we would obtain any further     <font color="blue">regulatory clearance</font>s or <font color="blue">premarket approval</font>s in a <font color="blue">timely manner</font> or at all,     and delays in obtaining <font color="blue">clearances</font> or approvals may <font color="blue">adversely</font> affect our     revenue growth, future <font color="blue">profitability</font> and ability to penetrate what otherwise     might be <font color="blue">lucrative markets</font> for our products</td>
    </tr>
    <tr>
      <td>We have begun to invest <font color="blue">significant</font> financial resources to <font color="blue">conduct clinical</font>     trials  of  our  products,  which  will reduce our <font color="blue">earnings during</font> the     <font color="blue">foreseeable future</font>, and which may not <font color="blue">ultimately provide data supportive</font> of     the use and <font color="blue">clinical efficacy</font> of our products</td>
    </tr>
    <tr>
      <td>We anticipate conducting <font color="blue">significant</font> <font color="blue">additional</font> clinical trial activity both     in the <font color="blue">United States </font>and abroad to collect further data that may support the     use and <font color="blue">clinical efficacy</font> of our products</td>
    </tr>
    <tr>
      <td>The cost of these <font color="blue">trials will</font> be     <font color="blue">significant</font>,  which  may  reduce  our  net income and earnings for the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>In addition, the results of our <font color="blue">clinical trials</font> may not ultimately produce     data that are supportive of our products over other treatment <font color="blue">alternative</font>s,     that <font color="blue">may support unfavorable <font color="blue">conclusions</font></font> regarding our <font color="blue">technology</font>, and that     ultimately  may  provide information that leads to a <font color="blue">decreased rate</font> of     adoption of our products for <font color="blue">balloon <font color="blue">kyphoplasty</font></font>, <font color="blue">which would harm</font> our     business and cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Finally, we may be unable to     complete the <font color="blue">clinical trials</font> for a variety of reasons, and <font color="blue">therefore may</font> not     be able to provide <font color="blue">additional</font> <font color="blue">clinical data</font> on our products</td>
    </tr>
    <tr>
      <td><font color="blue">Modifications </font>to our marketed devices may require new 510(k) <font color="blue">clearances</font> or     <font color="blue">premarket approval</font>s <font color="blue">or the FDA </font>may require us to <font color="blue">cease marketing</font> or recall     the modified devices until <font color="blue">clearances</font> are obtained</td>
    </tr>
    <tr>
      <td>Any <font color="blue">modification</font> to a 510(k)-cleared device that could <font color="blue">significant</font>ly affect     its safety or <font color="blue"><font color="blue">effective</font>ness</font>, or that <font color="blue">would constitute</font> a major change in its     intended  use, requires a new 510(k) clearance or, possibly, premarket     approval</td>
    </tr>
    <tr>
      <td>The FDA requires <font color="blue">every <font color="blue">manufacture</font>r</font> to make this <font color="blue">de<font color="blue">termination</font></font> in     the first instance, but the FDA can review any <font color="blue">manufacture</font>rapstas decision</td>
    </tr>
    <tr>
      <td>We     have <font color="blue">modified aspects</font> of our KyphX <font color="blue">instruments</font> without seeking new 510(k)     <font color="blue">clearances</font> because we believe that the <font color="blue">modification</font>s do not <font color="blue">significant</font>ly     affect the productapstas safety or <font color="blue"><font color="blue">effective</font>ness</font></td>
    </tr>
    <tr>
      <td>The FDA may not <font color="blue">agree with</font> any     of  our  <font color="blue">decisions</font> not to seek new <font color="blue">clearances</font> or approvals</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA     </font>requires us to seek 510(k) clearance or <font color="blue">premarket approval</font> for any of these     <font color="blue">modification</font>s to a <font color="blue">previously cleared</font> device, we may be required to cease     marketing or to recall the modified device until we obtain clearance or     approval,  and  we  may  be subject to <font color="blue">significant</font> regulatory fines or     penalties</td>
    </tr>
    <tr>
      <td>If we are unable to expand our <font color="blue">manufacturing</font> <font color="blue">capacity</font> in a <font color="blue">timely manner</font>, or     if we do not <font color="blue">accurately</font> project demand, we could have <font color="blue">excess <font color="blue">capacity</font></font> or     insufficient <font color="blue">capacity</font>, either of which <font color="blue">could <font color="blue">adversely</font> affect</font> our operating     results</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently <font color="blue">manufacture</font> substantially</font> all of our KyphX <font color="blue">instruments</font> in our     <font color="blue">facilities</font>  located  in  Sunnyvale,  California</td>
    </tr>
    <tr>
      <td>We plan to expand our     <font color="blue">manufacturing</font> <font color="blue">capacity</font> at this <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>In addition, we will be devoting     <font color="blue">significant</font> resources during 2006 and 2007 towards <font color="blue">establishing</font> our new     <font color="blue">facilities</font>  in  Neuchâtel, Switzerland that will include <font color="blue">manufacturing</font>     <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>We plan to <font color="blue">manufacture</font> a <font color="blue">secondary supply</font> of our KyphX <font color="blue">instruments</font>     in  this <font color="blue">facility</font>, in addition to <font color="blue">manufacturing</font> our <font color="blue">proprietary</font> <font color="blue">KyphOs     </font>calcium  phosphate  and  KyphX  HV-R  <font color="blue">bone cement</font></td>
    </tr>
    <tr>
      <td>We could experience     <font color="blue"><font color="blue">difficult</font>ies</font> and <font color="blue"><font color="blue">disruption</font>s</font> in the <font color="blue">manufacture</font> of our KyphX <font color="blue">instruments</font>     during <font color="blue">capacity</font> expansion in our Sunnyvale <font color="blue">facility</font>, prior to <font color="blue">bringing up</font>     our Neuchâtel <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>In both our Sunnyvale and Neuchâtel <font color="blue">facilities</font> we     could  also  face  the  <font color="blue">inability</font> to procure and install the <font color="blue">necessary</font>     <font color="blue">manufacturing</font> equipment, a shortage of <font color="blue">components used</font> in our products, a     lack of <font color="blue">availability</font> of qualified <font color="blue">manufacturing</font> personnel, <font color="blue"><font color="blue">difficult</font>ies</font> in     achieving  <font color="blue">consistent</font>  quality  control  from new <font color="blue">manufacturing</font> lines,     <font color="blue"><font color="blue">difficult</font>ies</font>  in  obtaining  or maintaining <font color="blue">compliance with</font> regulatory     <font color="blue">requirements mandated by</font> the <font color="blue">FDA and the European Union </font>and an <font color="blue">inability</font> to     maintain  sufficient <font color="blue">manufacturing</font> <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>We may experience delays,     <font color="blue"><font color="blue">disruption</font>s</font>, <font color="blue">capacity</font> constraints and other problems in our <font color="blue">manufacturing</font>     <font color="blue">operations</font>, and, as a result, <font color="blue">product shipments</font> to our <font color="blue">customers could</font> be     delayed, which would negatively impact our revenues, <font color="blue"><font color="blue">competitive</font> position</font>     and reputation</td>
    </tr>
    <tr>
      <td>If we are unable to expand our <font color="blue">manufacturing</font> <font color="blue">capacity</font> in a     <font color="blue">timely manner</font>, or if we do not <font color="blue">accurately</font> project demand, we will have     <font color="blue">excess <font color="blue">capacity</font></font> or insufficient <font color="blue">capacity</font>, either of <font color="blue">which could</font> seriously     harm our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Because injuries that occur <font color="blue">during <font color="blue">spine surgery</font></font> can be <font color="blue">significant</font>, we are     subject to an <font color="blue">increased risk</font> of <font color="blue">product liability</font> lawsuits and/or regulatory     action</td>
    </tr>
    <tr>
      <td>If we are sued in a <font color="blue"><font color="blue">product liability</font> action</font>, we could be forced to     pay substantial damages</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> <font color="blue">medical devices</font> that are <font color="blue">used on patients</font> in <font color="blue">spine surgery</font>     procedures</td>
    </tr>
    <tr>
      <td>Spine surgery, including <font color="blue">balloon <font color="blue">kyphoplasty</font></font>, involves risk of     <font color="blue">serious <font color="blue">complications</font></font>, including cardiac arrest, cerebrovascular accident,     myocardial infarction, pulmonary embolism, and death</td>
    </tr>
    <tr>
      <td>The use of <font color="blue">bone filler</font>     material by surgeons to fill the void created using our KyphX Inflatable     Bone Tamp <font color="blue">may also lead</font> to these <font color="blue">complications</font>, as a result of leakage of     the <font color="blue">bone filler</font> material into the <font color="blue">spinal canal</font> or <font color="blue">surrounding tissue</font> or for     other reasons</td>
    </tr>
    <tr>
      <td>We are aware that some of these <font color="blue">complications</font> have occurred     <font color="blue">during procedures</font> performed with our products, including our KyphX HV-R bone     cement and KyphOs <font color="blue">calcium phosphate</font>, and we have had to publicly report that     information <font color="blue">through filing</font> a Medical Device Report to the FDA or Vigilance     Reports in Europe</td>
    </tr>
    <tr>
      <td><font color="blue">Increased </font>reporting of <font color="blue">adverse events</font> in <font color="blue"><font color="blue">connection</font> with</font>     the  use  of  our  or  other <font color="blue">bone void filler materials during balloon</font>     <font color="blue">kyphoplasty</font>  could  expose  us  to <font color="blue">increased risk</font> of <font color="blue">product liability</font>     <font color="blue">litigation</font>, and our <font color="blue">current insurance coverage limits may</font> not be adequate     and we may not be able to obtain continued <font color="blue">product liability</font> coverage on     <font color="blue">commercially</font> reasonable terms, if at all</td>
    </tr>
    <tr>
      <td>Companies, including ours, which     produce devices for use in the spine, are subject to a <font color="blue">significant</font> risk of     <font color="blue">product liability</font> <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If any of our devices are found to have caused     or  <font color="blue">contributed</font> to any injury, we could be held liable for substantial     damages,  and our current <font color="blue">product liability</font> coverage limits may not be     adequate to <font color="blue">protect us from</font> any <font color="blue">liabilities</font> we <font color="blue">might incur</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability insurance</font> is expensive and may not be available     to us in the future on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>In addition, increased     reporting of <font color="blue">adverse events</font> may lead to <font color="blue">regulatory action by</font> the FDA which     <font color="blue">could <font color="blue">adversely</font> affect</font> our ability to market products and/or result in other     adverse  <font color="blue">consequences</font>  to our Company, our employees and our business,     including but not limited to civil and criminal penalties, recall, seizure,     and product withdrawal, which in turn <font color="blue">could <font color="blue">adversely</font> affect</font> our business     and our <font color="blue">financial condition</font> and cause our stock price to decline</td>
    </tr>
    <tr>
      <td>We are aware that a complaint, which we believe is a <font color="blue">qui tam complaint</font>, is     being <font color="blue">evaluated by</font> a US Attorneyapstas Office in <font color="blue"><font color="blue">connection</font> with</font> our marketing     and sales practices, including those relating <font color="blue">to the Medicare </font><font color="blue">reimbursement</font>     available to our <font color="blue">customer hospitals</font></td>
    </tr>
    <tr>
      <td>If a subpoena, or an <font color="blue">enforcement</font> or     other <font color="blue">action ultimately</font> results from this <font color="blue">investigation</font>, our business and     <font color="blue"><font color="blue">financial condition</font> could</font> be <font color="blue"><font color="blue">adversely</font> affected</font> <font color="blue">which could</font> cause our stock     price to decline</td>
    </tr>
    <tr>
      <td>We have learned that sometime in 2005, a US Attorneyapstas Office (USAO)     received a complaint that we believe is a <font color="blue">qui tam complaint</font> that alleges     <font color="blue">impropriety</font> in our <font color="blue">reimbursement</font> practices</td>
    </tr>
    <tr>
      <td>Although no subpoena has been     issued to us, <font color="blue">the USAO </font>in <font color="blue"><font color="blue">connection</font> with</font> this complaint is <font color="blue">investigating</font>     our sales and marketing practices, including those relating <font color="blue">to Medicare     </font><font color="blue">reimbursement</font> available to our <font color="blue">customer hospitals</font>, <font color="blue">based on</font> site-of-service,     for using Kyphonapstas products in surgery, and has <font color="blue">informally asked about</font> some     of our <font color="blue">documentation</font> that may be relevant to the <font color="blue">investigation</font></td>
    </tr>
    <tr>
      <td>We believe     we are in substantial <font color="blue">compliance with</font> the <font color="blue">healthcare laws relevant</font> to our     Company</td>
    </tr>
    <tr>
      <td>Even though we have not received a subpoena regarding the complaint     or its <font color="blue">allegations</font>, we are <font color="blue">voluntarily cooperating with</font> the USAO, to permit     <font color="blue">the USAO </font>to develop an informed opinion on whether or not to pursue any     action in <font color="blue"><font color="blue">connection</font> with</font> the complaint, although timing on that decision is     uncertain</td>
    </tr>
    <tr>
      <td>At  this  time, we do not know whether the outcome of the     <font color="blue">investigation</font> will have a material <font color="blue">adverse impact</font> to our business, and     <font color="blue">cannot assure</font> you regarding any <font color="blue">future path</font> USAO or any related <font color="blue">lawsuit may</font>     take</td>
    </tr>
    <tr>
      <td>If  an  <font color="blue">enforcement</font>  or  other  action results from the ongoing     <font color="blue">investigation</font>, our business and <font color="blue"><font color="blue">financial condition</font> could</font> be <font color="blue">adversely</font>     affected <font color="blue">which could</font> cause our stock price to decline</td>
    </tr>
    <tr>
      <td>We derive a <font color="blue">significant</font> portion of our operating results from non-US     sales, which are subject to <font color="blue"><font color="blue">additional</font> risks</font> arising from <font color="blue">international</font>     <font color="blue">operations</font> and sales</td>
    </tr>
    <tr>
      <td>Sales outside of the <font color="blue">United States </font>account for a <font color="blue">significant</font> percentage of     our  revenues  and  we  intend  to  continue to expand our presence in     <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td><font color="blue">International </font><font color="blue">net sales accounted</font> for dlra48dtta5 million,     or  <font color="blue">approximately</font>  16prca  of  <font color="blue">total net sales</font> in 2005</td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font>     <font color="blue">operations</font> and sales are subject to a number of <font color="blue">further risks</font> in addition to     those faced for our business, <font color="blue">generally</font> including:       * our products may sell at lower prices outside the United States;       * <font color="blue"><font color="blue">agreement</font>s may</font> be <font color="blue">difficult</font> to enforce;       * <font color="blue">receivables may</font> be <font color="blue">difficult</font> to <font color="blue">collect through</font> a foreign countryapstas         <font color="blue">legal system</font>;       * <font color="blue">foreign customers may</font> have <font color="blue">longer payment cycles</font>;       * <font color="blue">foreign countries</font> may impose <font color="blue">additional</font> withholding taxes or otherwise         tax our foreign income, impose tariffs or adopt other <font color="blue">restrictions</font> on         <font color="blue">foreign trade</font>;       * US <font color="blue">export licenses may</font> be <font color="blue">difficult</font> to obtain;       * <font color="blue">intellectual</font> property may be more <font color="blue">difficult</font> to acquire and enforce in         <font color="blue">foreign countries</font>, and copying of our products in <font color="blue">certain jurisdictions</font>         <font color="blue">may become widespread</font>;       * terrorist activity may interrupt <font color="blue">distribution</font> channels or impact our         customers or employees; and       * <font color="blue">fluctuations</font> in <font color="blue">exchange rates may affect product demand</font> and <font color="blue">adversely</font>         affect the <font color="blue">profitability</font>, in US dollars, of <font color="blue">products sold</font> in foreign         markets where payments are made in <font color="blue">local currencies</font></td>
    </tr>
    <tr>
      <td>Any one or more of these factors stated above could have an adverse effect     on our non-US <font color="blue">financial condition</font>, results of <font color="blue">operations</font> and business</td>
    </tr>
    <tr>
      <td>Since we <font color="blue">depend upon <font color="blue">distributor</font>s</font> in some markets, if we lose a <font color="blue">distributor</font>     or a <font color="blue">distributor</font> fails to perform, our <font color="blue">revenues will</font> be harmed in those     <font color="blue">geographic markets</font></td>
    </tr>
    <tr>
      <td>With the present exception of Canada and some of the <font color="blue">larger countries</font> in     Europe,  we  sell  our  KyphX  <font color="blue">instruments</font>  in <font color="blue">foreign markets through</font>     <font color="blue">distributor</font>s and <font color="blue">sales agents</font></td>
    </tr>
    <tr>
      <td>To the extent we rely on <font color="blue">distributor</font>s, our     success will depend upon the efforts of others, over which we may have     little control</td>
    </tr>
    <tr>
      <td>We <font color="blue">recently terminated</font> our relationship with <font color="blue">distributor</font>s in     <font color="blue">several foreign jurisdictions</font> and are in the process of <font color="blue">establishing</font>, or     have already established, new relationships in those and other geographic     regions</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also terminate</font> or modify other <font color="blue">distribution</font> relationships in     further <font color="blue">geographic locations</font> in the future</td>
    </tr>
    <tr>
      <td>If we lose a <font color="blue">distributor</font> or a     <font color="blue">distributor</font>  fails  to  perform,  our <font color="blue">revenues will</font> be harmed in those     <font color="blue">geographies</font>, and the market for our <font color="blue">products may also</font> be harmed in those     <font color="blue">geographies</font> as a result of the <font color="blue">distributor</font>apstas or agentapstas actions</td>
    </tr>
    <tr>
      <td><font color="blue">Alternative     </font><font color="blue">sales channels</font> are available in these <font color="blue">geographic markets</font>, however, their     <font color="blue">establishment</font> could consume substantial time and resources</td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on suppliers could limit</font> our ability to meet demand for our     products in a <font color="blue">timely manner</font> or within our budget</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent upon</font> outside suppliers to <font color="blue">provide us with key components</font>     <font color="blue">necessary</font> for the <font color="blue">manufacture</font> of our products</td>
    </tr>
    <tr>
      <td>In addition, we are presently     sourcing our KyphX Inflation Syringe and our KyphX HV-R Bone Cement from     single  suppliers,  without  any  present viable <font color="blue">alternative</font> suppliers     qualified</td>
    </tr>
    <tr>
      <td>Generally, since we obtain <font color="blue">components through purchase orders</font>     rather than long-term supply <font color="blue">agreement</font>s and do not maintain large volumes of     inventory, a product recall, <font color="blue">disruption</font> or <font color="blue">termination</font> of the supply of     components <font color="blue">could <font color="blue">adversely</font> affect</font> our <font color="blue">continued ability</font> to conduct business,     including causing:       * a <font color="blue">significant</font> increase in <font color="blue">manufacturing</font> costs associated with the need         to obtain <font color="blue">replacement components</font>;       * our <font color="blue">inability</font> to meet demand for our <font color="blue">instruments</font>, <font color="blue">which could</font> lead to         <font color="blue">customer dissatisfaction</font> and damage our reputation; and       * <font color="blue">delays associated with regulatory qualifications</font> required for use of         <font color="blue">replacement suppliers</font></td>
    </tr>
    <tr>
      <td>Any  one of these results <font color="blue">could harm</font> our sales and profits and make it     <font color="blue">difficult</font> to meet our business goals</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">effective</font>ly manage our growth, our <font color="blue">existing infrastructure may</font>     become strained, and as a result we may be unable to <font color="blue">increase sales</font> of our     KyphX <font color="blue">instruments</font> or generate <font color="blue">significant</font> revenue growth</td>
    </tr>
    <tr>
      <td>Our world-wide direct sales <font color="blue">organization</font> has increased from <font color="blue">approximately</font> 31     employees in October 2000 to over 425 employees in <font color="blue">December </font>2005, which we     believe represents <font color="blue">significant</font> growth over a <font color="blue">relatively</font> short period of     time</td>
    </tr>
    <tr>
      <td>Our  world-wide  <font color="blue">organization</font>  as  a  whole  has increased from     <font color="blue">approximately</font>  131  employees in October 2000 to over 880 employees in     <font color="blue">December </font>2005</td>
    </tr>
    <tr>
      <td>We intend to <font color="blue">continue growing rapidly</font></td>
    </tr>
    <tr>
      <td>The growth that we     have  experienced,  and in the <font color="blue">future likely will</font> experience, provides     <font color="blue">challenges</font> to our <font color="blue">organization</font>, requiring us to <font color="blue">rapidly expand</font> our personnel     and  <font color="blue">manufacturing</font>  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">hire sufficient</font>     personnel to meet our <font color="blue">growth goals</font> or may have <font color="blue">difficult</font>y managing such     <font color="blue">rapid growth</font></td>
    </tr>
    <tr>
      <td>As a result, our failure to recruit <font color="blue">additional</font> sales and other     <font color="blue">personnel may</font> result in our <font color="blue">inability</font> to meet our <font color="blue">projections</font></td>
    </tr>
    <tr>
      <td>Future growth     may strain our infrastructure, <font color="blue">operations</font>, product <font color="blue">development</font> and other     managerial  and  operating resources</td>
    </tr>
    <tr>
      <td>If our business <font color="blue">resources become</font>     strained, we may not be able to deliver <font color="blue">instruments</font> in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> our senior <font color="blue">management</font> team and <font color="blue">key personnel</font>, and the     loss of any of them <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">continued success depends</font> in part upon the continued <font color="blue">availability</font> and     <font color="blue">contributions</font> of our senior <font color="blue">management</font> team and <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>We have     entered  into  an  <font color="blue">employment <font color="blue">agreement</font> with</font> Richard W Mott, but this     <font color="blue">agreement</font> does not guarantee his service for any <font color="blue">specified period</font> of time</td>
    </tr>
    <tr>
      <td>We have not entered into employment <font color="blue">agreement</font>s with any of our other senior     <font color="blue">management</font> or <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>The loss of members of our senior <font color="blue">management</font> or     key  personnel, or our <font color="blue">inability</font> to attract and retain other qualified     personnel or advisors <font color="blue">could <font color="blue">adversely</font> affect</font> our business and financial     condition, <font color="blue">which could</font> cause our stock price to decline</td>
    </tr>
    <tr>
      <td>We may be <font color="blue"><font color="blue">adversely</font> affected</font> by the impact of <font color="blue"><font color="blue">environment</font>al</font> and safety     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We are subject to federal, state, local and <font color="blue">foreign laws</font> and <font color="blue">regulations</font>     governing the protection of the <font color="blue">environment</font> and <font color="blue">occupational health</font> and     safety, including <font color="blue">laws regulating</font> the disposal of <font color="blue">hazardous wastes</font> and the     health and safety of our employees</td>
    </tr>
    <tr>
      <td>We may be required to obtain permits for     <font color="blue">government</font>al authorities for certain <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we violate or fail to     <font color="blue">comply with</font> these laws and <font color="blue">regulations</font>, we <font color="blue">could incur</font> fines, penalties or     other sanctions, which <font color="blue">could <font color="blue">adversely</font> affect</font> our business and our financial     condition and cause our stock price to decline</td>
    </tr>
    <tr>
      <td>We <font color="blue">could incur</font> material     expenses in the future relating to <font color="blue">compliance with</font> future <font color="blue"><font color="blue">environment</font>al</font>     laws</td>
    </tr>
    <tr>
      <td>In addition, we could be held responsible for costs and damages     arising from any <font color="blue"><font color="blue">contamination</font> at</font> our present <font color="blue">facilities</font> or third-party     <font color="blue">waste disposal sites</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">costs could</font> be material</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot <font color="blue">completely</font></font>     eliminate the risk of <font color="blue">contamination</font> or injury resulting <font color="blue">from hazardous</font>     materials,  and  we  may  incur  material <font color="blue">liability as</font> a result of any     <font color="blue">contamination</font> or injury</td>
    </tr>
    <tr>
      <td>We may seek <font color="blue">additional</font> financing, <font color="blue">which could</font> result in dilution to our     <font color="blue">stockholders</font> or may not be available to us on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had dlra76dtta1 million of cash and <font color="blue">cash equivalents</font>     and dlra118dtta3 million of short-term <font color="blue">investment</font>s</td>
    </tr>
    <tr>
      <td>We currently believe that our     current  cash,  <font color="blue">cash equivalents</font>, <font color="blue">investment</font>s, and <font color="blue">cash generated from</font>     <font color="blue">operations</font> will be sufficient to meet our anticipated cash needs for at     least the next 12 months</td>
    </tr>
    <tr>
      <td>If existing cash, <font color="blue">cash equivalents</font>, and cash     generated from <font color="blue">operations</font> are insufficient to satisfy our <font color="blue">cash requirements</font>,     <font color="blue">whether as</font> a result of <font color="blue">possible <font color="blue">investment</font></font> in <font color="blue">new markets</font> or businesses     <font color="blue">through both internal</font> or external business <font color="blue">development</font>, expansion of product     lines, increased capital expenditures, <font color="blue">additional</font> <font color="blue">clinical trials</font>, expansion     of <font color="blue">product lines</font> or <font color="blue">investment</font> in <font color="blue">new markets</font> or businesses, or for other     reasons related to our business, we may seek to sell <font color="blue">additional</font> equity or     <font color="blue">debt securities</font> or obtain a credit <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>The sale of <font color="blue">additional</font> equity     or the sale of convertible <font color="blue">debt securities</font> could result in dilution to our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">additional</font> funds are <font color="blue">raised through</font> the issuance of debt     securities, these <font color="blue">securities could</font> have <font color="blue">rights senior</font> to those associated     with our <font color="blue">common stock</font>, and <font color="blue">could contain covenants</font> that <font color="blue">would restrict</font> our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">financing may</font> not be available to us when we need it     or it may not be <font color="blue">available on</font> favorable terms, if at all</td>
    </tr>
    <tr>
      <td>If we are unable     to obtain <font color="blue">adequate financing</font> when needed, we may have to delay, reduce the     scope of or eliminate our business <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">certificate</font>  of  <font color="blue">incorporation</font>  and by-laws include anti-takeover     provisions that may enable our <font color="blue">management</font> to resist an <font color="blue">unwelcome takeover</font>     <font color="blue">attempt by</font> a <font color="blue">third party</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">basic corporate documents</font> and <font color="blue">Delaware </font><font color="blue">law contain provisions</font> that     enable our <font color="blue">management</font> to attempt to resist a <font color="blue">takeover unless</font> it is deemed by     <font color="blue">management</font> and our <font color="blue">Board of <font color="blue">Directors </font></font>to be in the <font color="blue">best interests</font> of our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Those provisions might discourage, delay or prevent a change     in the control of our company or a change in our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Our Board of     <font color="blue">Directors </font><font color="blue">may also choose</font> to adopt further anti-takeover measures without     <font color="blue">stockholder approval</font></td>
    </tr>
    <tr>
      <td>The existence and adoption of these <font color="blue">provisions could</font>     <font color="blue">adversely</font> affect the <font color="blue">voting power</font> of holders of <font color="blue">common stock</font> and limit the     price that <font color="blue">investors might</font> be willing to pay in the future for shares of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have experienced and <font color="blue">may continue</font> to experience increases in our general     and <font color="blue">administrative costs as</font> a result of <font color="blue">additional</font> securities and corporate     <font color="blue">governance laws</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The Sarbanes-Oxley Act of 2002 that became law in July 2002, as well as the     rules and <font color="blue">regulations</font> subsequently implemented by the <font color="blue">SEC and the NASDAQ     </font>exchange  on  which we are listed, required <font color="blue">significant</font> changes to our     corporate  governance  practices</td>
    </tr>
    <tr>
      <td>These new rules and <font color="blue">regulations</font> have     resulted  in <font color="blue">increased legal</font> and <font color="blue">financial compliance costs</font>, make some     <font color="blue">activities</font> more <font color="blue">difficult</font>, time consuming and/or costly, and make it more     <font color="blue">difficult</font>  and  more expensive for us to obtain <font color="blue">directors</font> and officers     <font color="blue">liability insurance</font>, all of <font color="blue">which may affect</font> our <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>These new rules and <font color="blue">regulations</font> may also make it more <font color="blue">difficult</font> for us to     attract or retain <font color="blue">qualified executive officers</font> and members of our Board of     Directors, <font color="blue">particularly</font> to serve on our <font color="blue">Audit Committee</font></td>
    </tr>
    <tr>
      <td>We may experience     <font color="blue">additional</font> increases in our general and <font color="blue">administrative costs as</font> a result of     <font color="blue">additional</font> securities and corporate <font color="blue">governance laws</font> and <font color="blue">regulations</font> that may     be enacted in the future</td>
    </tr>
    <tr>
      <td>We can <font color="blue">provide no assurance</font> regarding our, or our <font color="blue">independent</font> auditorapstas,     <font color="blue">conclusions</font> after <font color="blue">December </font>31, 2005 with respect to the <font color="blue"><font color="blue">effective</font>ness</font> of our     <font color="blue">internal <font color="blue">control over financial</font></font> reporting</td>
    </tr>
    <tr>
      <td>Section 404 of the Sarbanes-Oxley Act of 2002 requires us to include an     internal control report from <font color="blue">management</font> in our <font color="blue">Annual Report </font>on Form 10-K     for the years ending on and after <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>The internal control     report must include a statement:         * about <font color="blue">management</font>apstas responsibility for <font color="blue">establishing</font> and maintaining         adequate <font color="blue">internal <font color="blue">control over financial</font></font> reporting;       * identifying the framework used by <font color="blue">management</font> to conduct the required         <font color="blue">evaluation</font> of the <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue">internal <font color="blue">control over financial</font></font>         reporting;       * concerning <font color="blue">management</font>apstas <font color="blue">assessment</font> of the <font color="blue"><font color="blue">effective</font>ness</font> of our internal         <font color="blue">control over financial</font> reporting as of the <font color="blue">period covered by</font> the Annual         Report, including a <font color="blue">statement as</font> to whether or not internal control over         financial reporting is <font color="blue">effective</font>; and       * that our <font color="blue"><font color="blue">independent</font> auditors</font> have issued an <font color="blue">attestation</font> report on         <font color="blue">management</font>apstas <font color="blue">assessment</font> of <font color="blue">internal <font color="blue">control over financial</font></font> reporting</td>
    </tr>
    <tr>
      <td>While  we  expended  <font color="blue">significant</font> resources in developing the <font color="blue">necessary</font>     <font color="blue">documentation</font> and <font color="blue">testing procedures</font> required by Section 404, given the     risks  inherent  in  the operation of <font color="blue"><font color="blue">internal controls</font> over financial</font>     reporting,  we  can <font color="blue">provide no assurance</font> as to our, or our <font color="blue">independent</font>     auditorapstas,  <font color="blue">conclusions</font>  after  <font color="blue">December </font> 31, 2005 with respect to the     <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue">internal <font color="blue">control over financial</font></font> reporting</td>
    </tr>
    <tr>
      <td>Although we     received <font color="blue">unqualified opinions as</font> of <font color="blue">December </font>31, 2005, if we are unable to     maintain <font color="blue">compliance with</font> all of the <font color="blue">requirements imposed by</font> Section 404, or     if we are unable to complete any <font color="blue">assessment</font> of our <font color="blue">internal controls</font>, or if     our <font color="blue">internal controls</font> are not designed or operating <font color="blue">effective</font>ly, we may     conclude that our <font color="blue">internal <font color="blue">control over financial</font></font> reporting is not <font color="blue">effective</font>     and our <font color="blue">external auditors may either disclaim</font> an <font color="blue">opinion as</font> it relates to     <font color="blue">management</font>apstas <font color="blue">assessment</font> of the <font color="blue"><font color="blue">effective</font>ness</font> of our internal control or may     issue a <font color="blue">qualified opinion on</font> the <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue">internal controls</font></td>
    </tr>
    <tr>
      <td><font color="blue">Investors  </font>may  lose  confidence  in  the <font color="blue">reliability</font> of our financial     statements,  <font color="blue">which could</font> cause the <font color="blue">market price</font> of our <font color="blue">common stock</font> to     decline and <font color="blue">which could</font> affect our business and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Recent changes in the required <font color="blue">accounting treatment</font> for <font color="blue">stock options will</font>     have a material negative <font color="blue">impact on</font> our <font color="blue">financial statements</font> and may affect     our stock price</td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2004, the <font color="blue">Financial Accounting Standards Board </font>issued Statement     of Financial Accounting Standards (SFAS) Nodtta 123(R), pursuant to which we     must  measure all stock-based compensation awards, including grants of     employee stock options, using a fair value-based method and <font color="blue">record such</font>     expense  in our consolidated <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>Currently, we disclose <font color="blue">such expenses on</font> a <font color="blue">pro forma basis</font> in the notes to     our consolidated <font color="blue">financial statements</font>, but we do not record a charge for     <font color="blue">employee stock option expense</font> in the <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>Once we begin to     <font color="blue">comply with</font> SFAS Nodtta 123(R) as of the beginning of fiscal year 2006, our     reported  earnings will decrease, <font color="blue">which may affect</font> our stock price</td>
    </tr>
    <tr>
      <td>In     addition, our reported <font color="blue">earnings may</font> have <font color="blue">increased volatility due</font> to the tax     impact and timing of <font color="blue">employee stock option exercises</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">facilities</font> are located near <font color="blue">known earthquake fault zones</font>, and the     occurrence of an earthquake or other <font color="blue">natural disaster</font> or <font color="blue">catastrophic event</font>     could cause damage to our <font color="blue">facilities</font> and equipment, <font color="blue">which could</font> require us     to cease or curtail <font color="blue">operations</font> and <font color="blue">could hurt</font> our revenues</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">facilities</font>  are located near <font color="blue">known earthquake fault zones</font> and are     vulnerable to <font color="blue">significant</font> <font color="blue">damage from</font> earthquakes</td>
    </tr>
    <tr>
      <td>We are <font color="blue">also vulnerable</font> to     <font color="blue">damage from</font> other types of <font color="blue">disasters</font>, including fires, floods, power loss,     <font color="blue">communications failures</font> and similar events including the effects of war or     acts of terrorism</td>
    </tr>
    <tr>
      <td>If any disaster of this sort were to occur, our ability     to operate our business at our <font color="blue">facilities</font> could be seriously or <font color="blue">completely</font>     impaired or destroyed and our <font color="blue">revenues could</font> be <font color="blue">significant</font>ly impacted as a     result of our <font color="blue">inability</font> to continue to supply products to our customers</td>
    </tr>
    <tr>
      <td>The     insurance we maintain may also not be adequate to cover our own losses     resulting from <font color="blue">disasters</font> or other business <font color="blue">interruptions</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> amount of our <font color="blue">United States </font>revenue is <font color="blue">dependent on</font> business     from  areas  prone  to  hurricanes,  and the occurrence of one or more     <font color="blue">significant</font> hurricanes or other <font color="blue">natural disaster</font>s in those <font color="blue">geographic areas</font>     could substantially <font color="blue">adversely</font> impact many of our customers &amp;apos  <font color="blue">operations</font>,     <font color="blue">which would harm</font> our <font color="blue">financial condition</font> and our revenues</td>
    </tr>
    <tr>
      <td>Many of our customers in the southeastern <font color="blue">United States </font>and the Gulf Coast     region have been <font color="blue"><font color="blue">adversely</font> affected</font> by one or more <font color="blue">major hurricanes during</font>     the  past  several  years,  and may be so affected in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">catastrophic storm activity</font> has in the past <font color="blue"><font color="blue">adversely</font> affected</font> our revenues     from, and business <font color="blue">activities</font> in, those regions, and could in the future     similarly  <font color="blue">adversely</font>  affect  our  revenues and <font color="blue">operations</font>, due to our     customers &amp;apos   decreased  ability  to  continue  their <font color="blue">operations</font> without     <font color="blue">significant</font>  <font color="blue">disruption</font></td>
    </tr>
    <tr>
      <td>We may also be entering a <font color="blue">historic period</font> of     <font color="blue">increased hurricane activity</font></td>
    </tr>
    <tr>
      <td>If any disaster of this sort were to occur in     the future, our <font color="blue">United States </font><font color="blue">revenues could</font> be <font color="blue">significant</font>ly impacted</td>
    </tr>
  </tbody>
</table>